Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

• Status: Recruiting
• Trial end date: 2026-01-06
• Target enrollment: 0
• Participant gender: All

Summary

Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery during covid-19 pandemics (the pep trial) is a multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications after cardiac surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China National Center for Cardiovascular Diseases
• Treatments: Ritonavir; Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Age ≥18 years

• COVID-19 nucleic acid test or antigen test positive history, without symptom or recover from COVID-19 related symptoms ≥2 weeks

• Receive open-chest cardiac surgery

• COVID-19 nucleic acid test and antigen test negative and no signs of pneumonia in chest CT

• Patients with written informed consent.

Exclusion Criteria:

• Emergency surgery

• eGFR ≤30ml/min

• Severe liver dysfunction

• Contraindication to nirmatrelvir/ritonavir or ursodeoxycholic acid